Tag Archives: Alan Carr

Albireo Pharma Inc Received its Third Buy in a Row

After Jefferies and Wedbush gave Albireo Pharma Inc (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr assigned a Buy rating to Albireo Pharma Inc today and set a price

Needham Keeps Their Buy Rating on Biohaven Pharmaceutical Holding Co Ltd

Needham analyst Alan Carr maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) today and set a price target of $36. The company’s shares opened today at $29.95. Carr wrote: “Biohaven released financial results yesterday and we

Needham Reaffirms Their Buy Rating on Rhythm Pharmaceuticals Inc

In a report released today, Alan Carr from Needham maintained a Buy rating on Rhythm Pharmaceuticals Inc (NASDAQ: RYTM), with a price target of $32. The company’s shares opened today at $28.58. Carr wrote: “Rhythm reported 1Q18 financial results today

Needham Thinks Theravance Biopharma’s Stock is Going to Recover

Needham analyst Alan Carr maintained a Buy rating on Theravance Biopharma (NASDAQ: TBPH) today and set a price target of $40. The company’s shares opened today at $24.86, close to its 52-week low of $21.27. Carr said: “Theravance provided a

Needham Reaffirms Their Buy Rating on Aquinox Pharmaceuticals

Needham analyst Alan Carr maintained a Buy rating on Aquinox Pharmaceuticals (NASDAQ: AQXP) today and set a price target of $25. The company’s shares opened today at $13.11. Carr said: “Aquinox reported 1Q18 financial results today and we spoke with

Needham Remains a Hold on Intercept Pharma

Needham analyst Alan Carr maintained a Hold rating on Intercept Pharma (NASDAQ: ICPT) today. The company’s shares opened today at $70.15. Carr wrote: “Intercept reported $28.5M in 1Q18 U.S. Ocaliva sales (-11% q/q), below our and consensus $32.0M ests. WW